<p>FAM110B Inhibits Non-Small Cell Lung Cancer Cell Proliferation and Invasion Through Inactivating Wnt/β-Catenin Signaling</p>

Abstract

Purpose: FAM110B is a member of the FAM110 family (family with sequence similarity 110), which is a component of the centrosome associated proteins. Previous studies have shown that FAM110B may be involved in the process of cell cycle and may play a role in carcinogenesis and tumor progression. Using an online database, we found that FAM110B may predict favorable prognosis in non-small cell lung cancer (NSCLC). Therefore, the role of FAM110B playing in NSCLC needs to be further investigated. Patients and Methods: Online databases and immunohistochemistry were used to predict the expression and prognostic value of FAM110B in NSCLC samples. Immunofluorescence staining was used to investigate the subcellular distribution of FAM110B. Western blot, MTT, colony formation, and matrigel invasion assay were used to detect the expression and the effect of FAM110B on mediating proliferation and invasion in NSCLC cell lines. Results: In this study, immunohistochemistry results showed that FAM110B expression significantly correlated with early TNM staging (P=0.020) and negative regional lymph node metastasis (P=0.006). Kaplan-Meier survival analysis found that the median survival time of patients with positive FAM110B expression (56.181±2.348 months) was significantly longer than those with negative FAM110B expression (47.701±2.997 months, P=0.024). Moreover, overexpression of FAM110B inhibited the proliferation and invasion of A549, H1299, and LK2 cell lines. Conversely, FAM110B RNAi exerted opposite effects in the above cell lines. Furthermore, FAM110B overexpression downregulated the active β-catenin, phosphorylation of GSK-3β (p-GSK-3β), cyclin B1, cyclin D1, MMP2, and MMP7, and upregulated the phosphorylation of β-catenin (p-β-catenin) in A549 and H1299 cells. Besides, the FAM110Binduced depressions of p-GSK-3β and active β-catenin were reversed after being treated with Wnt/β-catenin inhibitor, XAV-939. Conclusion: In summary, our results demonstrated that the overexpression of FAM110B restricts the proliferation and invasion of NSCLC cells by inhibiting Wnt/β-catenin signaling. Our study reveals the antitumor function of FAM110B in NSCLC and indicates that FAM110B is a potential therapeutic target.

Characterization of aging cancer-associated fibroblasts draws implications in prognosis and immunotherapy response in low-grade gliomas

“…For example, as a member of the FAM110 family (family with sequence similarity 110), FAM110B with an AUC value of 0.934 was downregulated in gene cluster A and the high-aging CAF score group ( Supplementary Figure S4 , Figure 3K , Figure 4I ). Previous studies demonstrated that FAM110B participated in the regulation of the cell cycle and predicted favorable prognosis in NSCLC ( Xie et al, 2020 ). In agreement with this study, FAM110B was found to be involved in the favorable gene set which was used to calculate the aging CAF score.…”

Establishment and verification of a prognostic model based on coagulation and fibrinolysis-related genes in hepatocellular carcinoma

“…The immune function of HCC patients with low expression of PDE2A showed a downward trend [ 42 ]. There are few studies on FAM110D gene, but some studies have found that another FAM110 gene, FAD110B, can inhibit the growth and invasion of lung adenocarcinoma by inactivating the Wnt/β-catenin signaling pathway [ 53 ]. FAM110A may induce the occurrence and progression of pancreatic cancer [ 54 ].…”

Exploration and Validation of Pancreatic Cancer Hub Genes Based on Weighted Gene Co-Expression Network Analysis and Immune Infiltration Score Analysis

“…39 FAM110B has also been demonstrated to decrease the proliferation and differentiation of lung small-cell carcinoma. 40 Ank2 is mainly expressed in genes associated with human breast cancer and autism risk. The DPYD Gene May Have the Capacity to Enhance PC Cell Proliferation and Differentiation, Thereby Reducing Patient Survival Time Five genes, including DPYD, FXYD6, MAP6, FAM110B, and ANK2, were discovered to have survival differences after the 26 genes examined in this study were validated in the GEPIA website.…”